Latest News - Retina

Friday, July 21, 2017 | Clinical Trials, Retina, Alimera Sciences

New Data Reveal Real-World Benefits of Iluvien Treatment

The latest data from an ongoing audit of real-life UK clinical practice published online in Eye show the number of chronic diabetic macular edema (DME) patients with 6/12 vision, DVLA’s minimum …

Read the full story

Thursday, July 20, 2017 | Retina, Spark Therapeutics

Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational Luxturna (Voretigene Neparvovec) from FDA

Spark Therapeutics announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the FDA have designated investigational Luxturna (voretigene neparvovec) as a drug …

Read the full story

Monday, July 10, 2017 | Retina, Psivida

pSivida Out-Licenses EMEA Rights for Durasert Treatment for Posterior Segment Uveitis While Retaining US Commercial Rights

pSivida announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences that grants Alimera rights to pSivida’s Durasert 3-year treatment for posterior segment …

Read the full story

Friday, June 30, 2017 | Retina, AMD

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

NightstaRx announced the completion of a $45 million Series C financing transaction, the proceeds of which will be used for the upcoming phase 3 trial for Nightstar’s lead product candidate, NSR…

Read the full story

Thursday, June 29, 2017 | Medical Studies, Retina, AMD

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms

Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study. "Blood cancers, which most recent…

Read the full story

Thursday, June 22, 2017 | Retina, Psivida

pSivida Submits Marketing Authorization Application for Approval of Durasert 3-Year Treatment for Posterior Segment Uveitis in the EU

pSivida Corp. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market the company’s Durasert 3-year treatment for posterior s…

Read the full story

Thursday, June 22, 2017 | Clinical Trials, Retina, AMD

RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals announced the completion of enrollment in its phase 1/2 study RXI-109-1501. This multicenter, multidose, dose escalation trial is being conducted in patients with advanced neovascu…

Read the full story

Wednesday, June 21, 2017 | Product Releases, Retina, Bausch+Lomb

Bausch + Lomb Unveils AMD Virtual Experience with State-of-the-Art Technology at Optometry’s Meeting

Bausch + Lomb announced the launch of a new virtual reality tool using state-of-the-art technology. The Age-Related Macular Degeneration (AMD) Virtual Experience, unveiled during the annual meeting of…

Read the full story

Monday, June 19, 2017 | Partnerships, Retina

Vital Art and Science Announces License Agreement with Genentech for Its mVT Service

Vital Art and Science announced that it has signed a license agreement with Genentech for the use of Vital Art and Science’s mVT App service in Genentech’s ophthalmology clinical studies. …

Read the full story

Thursday, June 15, 2017 | Medical Studies, Retina, AMD

Aflibercept May Be Effective for Resistant Exudative AMD

Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report. "…

Read the full story

Wednesday, May 24, 2017 | Retina

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP

ProtoKinetix announced that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing. The stud…

Read the full story

Wednesday, May 17, 2017 | Retina

University of Birmingham: Eye Drops May Treat Age-Related Blindness

Scientists at the University of Birmingham in the UK say they have developed a type of eye drop that could potentially revolutionize the treatment of age-related macular degeneration (AMD), according …

Read the full story

Monday, May 15, 2017 | Medical Studies, Retina

Intravitreous Ranibizumab Cost-Effective for Some Patients With Proliferative Diabetic Retinopathy

Intravitreous ranibizumab appears to be cost-effective in patients with proliferative diabetic retinopathy (PDR) who have vision-impairing diabetic macular edema (DME), according to data from the Diab…

Read the full story

Tuesday, May 09, 2017 | Medical Studies, Retina

Robot Performs First-Ever Surgery Inside Human Eye

In a medical first, surgeons have used a robot to operate inside the human eye, greatly improving the accuracy of a delicate surgery to remove fine membrane growth on the retina. Such growth distorts …

Read the full story

Tuesday, May 09, 2017 | Medical Studies, Retina

Cell Replacement Could Restore Vision Lost to Neurodegeneration

Scientists have demonstrated the capacity to grow specialized neurons that relay visual data to the brain, creating a source of cells for future treatments of glaucoma and other optic neurodegenerativ…

Read the full story
Load More